Nitin K Damle

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi request reprint Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
    Nitin K Damle
    Oncology Discovery Research, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    Curr Opin Pharmacol 3:386-90. 2003
  2. ncbi request reprint Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
    Nitin K Damle
    Oncology Discovery Research, Wyeth Pharmaceuticals, 200 4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Expert Opin Biol Ther 4:1445-52. 2004
  3. ncbi request reprint Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22
    John F DiJoseph
    Oncology Discovery, Wyeth Research, 200 4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Cancer Immunol Immunother 54:11-24. 2005
  4. ncbi request reprint Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
    John F DiJoseph
    Oncology Discovery Research, Wyeth Research, Pearl River, New York 10965, USA
    Clin Cancer Res 12:242-9. 2006
  5. ncbi request reprint CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab
    John F DiJoseph
    Oncology Discovery, Wyeth Research, 200 4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Cancer Immunol Immunother 56:1107-17. 2007
  6. ncbi request reprint Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
    John F DiJoseph
    Oncology Discovery, Wyeth Research, Pearl River, New York 10965, USA
    Clin Cancer Res 10:8620-9. 2004
  7. ncbi request reprint Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples
    Erwin R Boghaert
    Wyeth Discovery Research Oncology, 401 North Middletown Rd, Pearl River, NY 10965, USA
    Cancer Chemother Pharmacol 61:1027-35. 2008
  8. ncbi request reprint Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy
    Erwin R Boghaert
    Wyeth Research, Pearl River, NY 10965, USA
    Int J Oncol 28:675-84. 2006
  9. ncbi request reprint Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts
    Erwin R Boghaert
    Wyeth Discovery Oncology and Wyeth Discovery Chemical and Screening Sciences, Pearl River, New York, USA
    Clin Cancer Res 10:4538-49. 2004
  10. ncbi request reprint Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
    John F DiJoseph
    Department of Oncology Discovery, Wyeth Research, Pearl River, NY 10965, USA
    Blood 103:1807-14. 2004

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
    Nitin K Damle
    Oncology Discovery Research, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    Curr Opin Pharmacol 3:386-90. 2003
    ..Antibody-targeted chemotherapy with immunoconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Mylotarg), is a clinically validated therapeutic strategy for the treatment of human cancer...
  2. ncbi request reprint Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
    Nitin K Damle
    Oncology Discovery Research, Wyeth Pharmaceuticals, 200 4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Expert Opin Biol Ther 4:1445-52. 2004
    ..A number of tumour-targeted immunoconjugates of calicheamicin are being explored preclinically at present for their therapeutic applications...
  3. ncbi request reprint Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22
    John F DiJoseph
    Oncology Discovery, Wyeth Research, 200 4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Cancer Immunol Immunother 54:11-24. 2005
    ..Based on these results, a calicheamicin conjugate of g5/44, CMC-544, was selected for further development as a targeted chemotherapeutic agent for the treatment of B-cell malignancies...
  4. ncbi request reprint Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
    John F DiJoseph
    Oncology Discovery Research, Wyeth Research, Pearl River, New York 10965, USA
    Clin Cancer Res 12:242-9. 2006
    ..Rituximab is a CD20-targeted antibody commonly used in B-NHL therapy. Here, we describe antitumor efficacy of a combination of CMC-544 and rituximab against B-cell lymphoma (BCL) in preclinical models...
  5. ncbi request reprint CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab
    John F DiJoseph
    Oncology Discovery, Wyeth Research, 200 4604, 401 North Middletown Road, Pearl River, NY 10965, USA
    Cancer Immunol Immunother 56:1107-17. 2007
    ....
  6. ncbi request reprint Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
    John F DiJoseph
    Oncology Discovery, Wyeth Research, Pearl River, New York 10965, USA
    Clin Cancer Res 10:8620-9. 2004
    ..CMC-544 is a CD22-targeted immunoconjugate of calicheamicin and exerts a potent cytotoxic effect against CD22+ B-cell lymphoma. This study evaluated antitumor efficacy of CMC-544 against systemically disseminated B-cell lymphoma...
  7. ncbi request reprint Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples
    Erwin R Boghaert
    Wyeth Discovery Research Oncology, 401 North Middletown Rd, Pearl River, NY 10965, USA
    Cancer Chemother Pharmacol 61:1027-35. 2008
    ..The method should discriminate between PK of the antibody moiety and PK of the conjugated calicheamicin (CM)...
  8. ncbi request reprint Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy
    Erwin R Boghaert
    Wyeth Research, Pearl River, NY 10965, USA
    Int J Oncol 28:675-84. 2006
    ..The results showed that using 'non-specific' immunoglobulin for passive targeting of calicheamicin might be an effective mode of cancer therapy...
  9. ncbi request reprint Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts
    Erwin R Boghaert
    Wyeth Discovery Oncology and Wyeth Discovery Chemical and Screening Sciences, Pearl River, New York, USA
    Clin Cancer Res 10:4538-49. 2004
    ..Because Le(y) is highly expressed on carcinomas of colon, breast, lung, ovary, and prostate, a CalichDMH conjugate targeting Le(y) could provide a treatment option for various cancers...
  10. ncbi request reprint Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
    John F DiJoseph
    Department of Oncology Discovery, Wyeth Research, Pearl River, NY 10965, USA
    Blood 103:1807-14. 2004
    ..Thus, CD22-targeted delivery of CalichDMH is a potent and effective preclinical therapeutic strategy for BCLs. The strong antitumor profile of CMC-544 supports its clinical evaluation as a treatment option for B-lymphoid malignancies...
  11. doi request reprint Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP
    John F DiJoseph
    Oncology Discovery, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    Cancer Chemother Pharmacol 67:741-9. 2011
    ..Here, we describe anti-tumor efficacy of CMC-544, CHOP or CVP against human BCL xenografts...
  12. ncbi request reprint Biopharmaceutical drug discovery using novel protein scaffolds
    Davinder S Gill
    Wyeth Research, Biological Technologies 87 CambridgePark Drive, Cambridge, Massachusetts 02140, USA
    Curr Opin Biotechnol 17:653-8. 2006
    ..Further progress in the field will permit the commercially successful development of sophisticated protein therapeutics against complex disease targets...
  13. ncbi request reprint Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells
    Lyka Potla
    Oncology Immunology Division, Wyeth Ayerst Research, 200 4604, 401 North Middletown Road, Pearl River, NY 10965 1299, USA
    Cancer Lett 175:187-95. 2002
    ..Because the function of E-cadherin is associated with contact inhibition of HT29 cells, phosphorylation of E-cadherin and beta-catenin by activation of EphA1 is one possible mechanism by which HT29 cells alleviate contact inhibition...
  14. ncbi request reprint B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model
    Kyri Dunussi-Joannopoulos
    Department of Inflammation, Wyeth Research, Cambridge, MA, USA
    Blood 106:2235-43. 2005
    ....
  15. doi request reprint Antibody-drug conjugates ace the tolerability test
    Nitin K Damle
    Nat Biotechnol 26:884-5. 2008